 




<DOCTITLE>Prospective Grant of Exclusive License: Macrophage Stimulating Protein </DOCTITLE>


<AGENCY>
AGENCY:

 National Institutes of Health, Public Health Service, DHHS.

 
</AGENCY>
<ACTION>
ACTION:

 Notice.

 

</ACTION>
<SUMMARY>
SUMMARY:

 This is notice, in accordance with 35 U.S.C. 209(c)(1) 
and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services,
is contemplating the grant of a limited field of use exclusive license in the United States to practice the invention
embodied in U.S. Patent Number 5,219,991, filed on September 21, 1990, and issued on June 15, 1993, entitled ``Macrophage
Stimulating Protein'', to Toyobo Co., Ltd., having a place of business in Cambridge, Massachusetts. The patent rights
in this invention have been assigned to the United States of America. 


The patent claims macrophage stimulating protein (MSP) and further relates to antibodies to MSP. It also claims a
method of purifying MSP. 
The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published
Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. 
The field of use would be limited to the use of MSP as an anti-fungal agent, in opportunistic infections in immunocompromised
individuals and against viral or mycobacterial infections. 


</SUMMARY>
<ADDRESS>
ADDRESSES:

 Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated
license should be directed to: Leopold J. Luberecki, Jr., J.D., Technology Licensing Specialist, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard, Box 13, Rockville, MD 208523804. Telephone:
(301) 4967735, ext. 223; Facsimile: (301) 4020220. Properly filed competing applications for a license
filed in response to this notice will be treated as objections to the contemplated license. Only written comments
and/or application for a license which are received by the NIH Office of Technology Transfer on or before February
27, 1995, will be considered. 




Dated: December 16, 1994.


</ADDRESS>
<SIGNER>
Barbara M. McGarey, 

</SIGNER>
<SIGNJOB>
Deputy Director, Office of Technology Transfer. 


</SIGNJOB>
<FRFILING>
[FR Doc. 9431768 Filed 122394; 8:45 am]

</FRFILING>
<BILLING>
BILLING CODE 414001P
</BILLING>


